Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification

Nat Rev Neurol. 2017 Dec;13(12):710-712. doi: 10.1038/nrneurol.2017.161. Epub 2017 Nov 17.

Authors

Kalliopi Pitarokoili¹, Ralf Gold¹

Affiliation

¹ Department of Neurology, Ruhr University, St Josef-Hospital, Gudrunstrasse 56, 44791 Bochum, Germany.

PMID: 29146954
DOI: 10.1038/nrneurol.2017.161

No abstract available

Publication types

News

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Viral / immunology
Humans
Immunologic Factors / adverse effects*
JC Virus / immunology*
Leukoencephalopathy, Progressive Multifocal / chemically induced*
Leukoencephalopathy, Progressive Multifocal / diagnosis*
Leukoencephalopathy, Progressive Multifocal / epidemiology
Leukoencephalopathy, Progressive Multifocal / immunology
Multiple Sclerosis / drug therapy*
Natalizumab / adverse effects*
Risk Assessment*

Substances

Antibodies, Monoclonal, Humanized
Antibodies, Viral
Immunologic Factors
Natalizumab